Research Topics
Genomes and GenesSpecies | Michael LubbertSummaryAffiliation: University Hospital Country: Germany Publications
| Collaborators
|
Detail Information
Publications
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyMichael Lubbert
Dept of Medicine, Div Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
Haematologica 97:393-401. 2012....
Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patientsM Lubbert
Division of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
Bone Marrow Transplant 44:585-8. 2009....- Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for ReseMichael Lubbert
Albert Ludwigs University, Freiburg, Germany
J Clin Oncol 29:1987-96. 2011..To compare low-dose decitabine to best supportive care (BSC) in higher-risk patients with myelodysplastic syndrome (MDS) age 60 years or older and ineligible for intensive chemotherapy... - Advances in the treatment of acute myeloid leukemia: from chromosomal aberrations to biologically targeted therapyMichael Lubbert
Division of Hematology Oncology, Department of Medicine, University of Freiburg Medical Center, Freiburg, Germany
J Cell Biochem 104:2059-70. 2008..The use of a variety of molecular biology techniques have identified a large number of genomic abnormalities; the challenge of the next several decades is to identify specific therapies for these molecular defects... - Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allograftingM Lubbert
Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
Bone Marrow Transplant 45:627-32. 2010..Objective responses, including continuous complete donor chimerism, occurred also in patients with poor-risk cytogenetics... 
In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studiesBjörn Hackanson
Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
Ann Hematol 84:32-8. 2005..Other, thus far unidentified hypermethylated genes may also be targets for demethylating agents...- Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patientsBjörn Rüter
Division of Hematology Oncology, Department of Internal Medicine I, Albert Ludwigs University Freiburg, Freiburg, Germany
Cancer 106:1744-50. 2006..Although at least 2 consolidating courses after best response usually are performed, the response to treatment after disease recurrence has not been systematically studied to date... - Myelodysplastic syndrome in transformation to acute myeloid leukemia presenting with diabetes insipidus: due to pituitary infiltration association with abnormalities of chromosomes 3 and 7Claudia I Muller
Department of Haematology Oncology, University of Freiburg Medical Center, Hugstetter Strasse 55, D 79106 Freiburg, Germany
Eur J Haematol 69:115-9. 2002..J. Haematol. 2001: 66: 66-69). Our report of an MDS with trilineage dysplasia and these karyotypic changes associated with DI indicates that this new entity may also include preleukemic cases... - The silence of the genes: epigenetic disturbances in haematopoietic malignanciesBjörn Hackanson
University of Freiburg Medical Center, Department of Hematology Oncology, 79106 Freiburg, Germany
Expert Opin Ther Targets 9:45-61. 2005.... - DNA hypermethylation of myeloid cells, a novel therapeutic target in MDS and AMLClaudia I Muller
University of Freiburg Medical Center, Department Internal Medicine I, Div Hematology Oncology, Albert Ludwigs University, Hugstetter Str, D 79106 Freiburg, Germany
Curr Pharm Biotechnol 7:315-21. 2006..g. with inhibitors of histone deacetylase activity... - Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemiaRainer Claus
Division Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany Electronic address
Leuk Res 37:190-6. 2013..In conclusion, complex DAC-induced DNA methylation changes occur very early and imply mechanisms distinct from non-hypomethylating cytosine analogs... - HDAC6 as a target for antileukemic drugs in acute myeloid leukemiaBjörn Hackanson
Department of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
Leuk Res 36:1055-62. 2012..Preferential acetylation of α-tubulin implies that ST80 might exert its antileukemic effect not through histone reacetylation but rather through inhibition of HDAC6... - MeDIP coupled with a promoter tiling array as a platform to investigate global DNA methylation patterns in AML cellsArzu Yalcin
Division of Hematology Oncology, Department of Medicine, University Medical Center Freiburg, Germany
Leuk Res 37:102-11. 2013.... - Hematologic and molecular spontaneous remission following sepsis in acute monoblastic leukemia with translocation (9;11): a case report and review of the literatureClaudia I Muller
Department of Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, Freiburg, Germany
Eur J Haematol 73:62-6. 2004..Balanced translocations such as in core binding factor (CBF) leukemias appear somewhat overrepresented. We speculate that AML-specific T cells might be relevant for induction of spontaneous remission and need to be further investigated... - The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cellsMaika Almstedt
Department of Medicine, Division Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany
Leuk Res 34:899-905. 2010..The susceptibility of DAC-treated AML cell lines to antigen-specific T-cell recognition has clear implications for future clinical trials combining DAC and specific immunotherapy in AML... - Regulation of the adaptor molecule LAT2, an in vivo target gene of AML1/ETO (RUNX1/RUNX1T1), during myeloid differentiationJesús Duque-Afonso
Department of Haematology Oncology, University of Freiburg, Hugstetter Strasse 55, Freiburg, Germany
Br J Haematol 153:612-22. 2011.... - Reversal of p15/INK4b hypermethylation in AML1/ETO-positive and -negative myeloid leukemia cell linesTobias Berg
Department of Medicine, Division of Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
Leuk Res 31:497-506. 2007..Further studies of AML1/ETO as a modifier of the epigenotype and sensitivity of myeloid cells to inhibitors of DNMTs and HDACs appear warranted... - Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agentsRainer Claus
Department Internal Medicine I, Division Hematology Oncology, University of Freiburg Medical Center, Hugstetterstrasse 55, D 79106 Freiburg, Germany
Semin Oncol 32:511-20. 2005..Thus, demethylating agents and histone deacetylase inhibitors may also induce a T-cell-mediated antileukemic or antitumor effect... - Transcriptional upregulation of p21/WAF/Cip1 in myeloid leukemic blasts expressing AML1-ETOTobias Berg
Department of Medicine, Division Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
Haematologica 93:1728-33. 2008..The increased expression of p21/WAF/Cip1 in primary leukemic blasts suggests that elevated p21/WAF/Cip1 levels may contribute to specific features observed in AML1-ETO positive leukemia... - The hematopathological basis for studying effects of the demethylating agent 5-aza-2'-deoxycytidine (decitabine) in myelodysplasiaHans Eckart Schaefer
Institute of Pathology, University of Freiburg, Freiburg, Germany
Ann Hematol 84:67-79. 2005..Emphasis is placed on itemizing the broad spectrum of cytologic and histologic stigmata defining the myelodysplastic categories that are to be considered in this study... - Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcomeBarbara Deschler
Haematologica 98:208-16. 2013.... - Occurrence of a germinoma 22 years after resection of a mature cerebral teratomaWibke G Janzarik
Department of Neurology, Neurocenter, University of Freiburg, Freiburg, Germany
J Neurooncol 88:217-9. 2008..The correct diagnosis could only be confirmed in a second cerebral biopsy, allowing for proper treatment with radiation therapy. The need to consider metachronous germinoma in this setting is discussed... - Epigenetic modification of CCAAT/enhancer binding protein alpha expression in acute myeloid leukemiaBjörn Hackanson
Department of Molecular Virology, Immunology and Medical Genetics, Division of Human Cancer Genetics, College of Pharmacy, Ohio State University, Columbus, Ohio, USA
Cancer Res 68:3142-51. 2008..Our results indicate that epigenetic alterations of C/EBP alpha are a frequent event in AML and that epigenetic treatment can result in down-regulation of a key hematopoietic transcription factor... - The role of X-inactivation in the gender bias of patients with acquired alpha-thalassaemia and myelodysplastic syndrome (ATMDS)Peter S Haas
Division of Haematology and Oncology, University of Freiburg Medical Centre, Freiburg, Germany
Br J Haematol 144:538-45. 2009..This study ruled out this hypothesis by investigating the pattern of ATRX inactivation in a cross-sectional analysis of normal females at ages ranging from newborn to 90 years... - Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatmentMichael Daskalakis
Department of Hematology, University of Freiburg Medical Center, Freiburg, Germany
Blood 100:2957-64. 2002.... - Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instabilityPeter S Haas
Department of Medicine, Division of Hematology/Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, D-79106 Freiburg, Germany
Leuk Res 30:338-42. 2006..8/9 abnormalities were gains or losses of entire chromosomes. The rate and pattern of cytogenetic evolution are thus not higher than in historical MDS cohorts not receiving specific treatment... - p53 Germline mutation in a patient with Li-Fraumeni Syndrome and three metachronous malignanciesClaudia Pötzsch
Div Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, 79106 Freiburg i Brsg, Germany
J Cancer Res Clin Oncol 128:456-60. 2002..Other malignancies diagnosed early in life in relatives of the mother were: prostate cancer, stomach cancer, and carcinoma of the larynx... - Autologous hematopoietic stem cell transplantation for myelodysplastic syndromes: which cell source is preferable?Michael Lubbert
Department of Hematology Oncology, Albert Ludwigs University, Freiburg, Germany
Haematologica 91:723A. 2006 - Decitabine in acute myeloid leukemiaMichael Lubbert
Department of Medicine, Division of Hematology Oncology, University of Freiburg Medical Center, Freiburg, Germany
Semin Hematol 42:S38-42. 2005..This review will provide a summary of epigenetic processes in AML and the role of the demethylating agent 5-aza-2'-deoxycytidine (decitabine; Dacogen, MGI Pharma, Inc, Bloomington, MN)... - Immune response as a possible mechanism of long-lasting disease control in spontaneous remission of MLL/AF9-positive acute myeloid leukemiaClaudia Müller-Schmah
Department of Hematology and Oncology, University of Freiburg Medical Center, Hugstetter Straße 55, 79106 Freiburg, Germany
Ann Hematol 91:27-32. 2012..When the patient's natural killer (NK) cells (obtained in 2007) were tested against the K562 cell line, upregulation of CD107 occurred, implying that long-term CR in this patient could be due to NK cell-mediated disease control... - Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?Utz Krug
Department of Medicine, Hematology Oncology, University of Munster, Munster, Germany
Curr Opin Hematol 17:85-90. 2010..The potential and limitations of the established cytotoxic chemotherapy for acute myeloid leukemia have been assessed by recent large-scale clinical trials. A further progress would require the contribution of alternative approaches... - Acute myeloid leukemia: epidemiology and etiologyBarbara Deschler
Department of Hematology Oncology, University of Freiburg, Freiburg, Germany
Cancer 107:2099-107. 2006..In contrast to these genetic alterations, epigenetic lesions, e.g., promoter silencing by hypermethylation of the p15/INK4b and other genes, are increasingly recognized as important in the pathogenesis of AML... - New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patientsDetlef Haase
Department of Hematology and Oncology, University of Gottingen, Gottingen, Germany
Blood 110:4385-95. 2007..Our analyses offer new insights into the prognostic significance of rare chromosomal abnormalities and specific karyotypic combinations in MDS... - Inhibitors of DNA methylation and histone deacetylation independently relieve AML1/ETO-mediated lysozyme repressionRainer Claus
Division Hematology/Oncology, University of Freiburg Medical Center, Hugstetter Str. 55, Freiburg D-79106, Germany
J Leukoc Biol 80:1462-72. 2006..Interestingly, inhibitors of DNMTs and HDACs independently relieve repression of this CpG-poor gene in AML1/ETO-positive cells... - CXCR4 is a prognostic marker in acute myelogenous leukemiaAnke C Spoo
Department of Medicine, Freiburg University Hospital, Germany
Blood 109:786-91. 2007..These findings warrant further investigation into the role of CXCR4 in AML and suggest that CXCR4 should be incorporated into the risk assessment of AML patients... - Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETOManfred Fliegauf
Division of Hematology Oncology, University of Freiburg Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
Oncogene 23:9070-81. 2004..The possible role of WBSCR5 in normal and malignant hematopoiesis warrants further study... - Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine)Michael Lubbert
Department of Hematology Oncology, University of Freiburg, Medical Center, Hugstetter Str 55, D 79106 Freiburg, Germany
Leuk Res 28:1267-71. 2004..In conclusion, restoration of nonclonal hematopoiesis may be the predominant effect of DAC both in early and late stages of treatment, at least in patients achieving a hematologic and cytogenetic response... - Epigenetic targets in hematopoietic malignanciesRainer Claus
Department Internal Medicine I, Division Hematology/Oncology, University of Freiburg Medical Center, Hugstetter Str, D-79106 Freiburg, Germany
Oncogene 22:6489-96. 2003..Studies combining a 're-expressor' strategy with inhibitors of Dnmts and HDACs are underway. Thus, resensitization to biological agents such as retinoids, colony-stimulating factors and other differentiation inducers may be envisioned... - DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical resultsWerner Digel
Department Internal Medicine, Division Hematology/Oncology, University of Freiburg Medical Center, Hugstetterstr. 55, D- 79106 Freiburg, Germany
Crit Rev Oncol Hematol 55:1-11. 2005..Clinical trials of both groups of agents have been performed, and novel demethylating agents which are not incorporated into DNA offer further perspectives for epigenetic therapy of lung cancer and other malignancies...